Pipelines & Targets
Pipeline

We strive to develop innovative therapies by strategically focusing on genetically defined diseases. Our clinical pipeline is focused on bezuclastinib, a highly selective and potent KIT inhibitor with the potential to provide a real solutions for patients. Our research pipeline leverages our world-class research and development team to advance our preclinical assets.

Clinical Programs
Research Programs
Cogent Research Program pipeline graphic

Targets

With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

KIT
KIT is a gene that encodes for receptor tyrosine kinases, which transmit signals from the cell surface into the cell through signal transduction. Mutated KIT plays a crucial role in the occurrence of some cancers. When stem cell factor binds to KIT, its protein is activated and phosphorylation leads to the activation of a series of proteins in multiple signaling pathways. Cogent’s KIT inhibitor, bezculastinib, was designed to hit KIT D816V, a common mutation in SM and GIST and is currently in late stage development for Advanced and Nonadvanced Systemic Mastocytosis, as well as Gastrointestinal Stromal Tumors.
FGFR2
FGFR2 is a gene that provides instructions to create proteins that are involved in important processes such as cell proliferation and maturation, bone development, and angiogenesis. FGFR2 and FGFR3 are altered in many solid tumors. Unmet need remains for therapies that target 2/3 without hitting FGFR1. Cogent is currently in Candidate Selection for a program targeting FGFR2.
ErbB2 Mut
ErbB2 is a gene that encodes for receptor tyrosine kinases. Mutations in this gene have been shown to play an oncogenic role and to be connected to multiple solid cancers. ErbB2 is in the EGFR family of receptor tyrosine kinases and mutated or amplified ErbB2 is a driver of tumorigenesis. Current therapies address amplification and few cover all the relevant ErbB2 mutations. Cogent is building a therapy that targets common ErbB2 mutations underserved in the market and is currently in lead-generation with this program.
Scroll to Top
lead-Cole-P
Cole Pinnow

Chief Commercial Officer

Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical industry, with a specific focus on oncology. Before joining Cogent as Chief Commercial Officer, he served at Pfizer as the Global Franchise Lead for its Genitourinary, Lung and Breast Oncology Businesses. In this role, he oversaw the global launch and lifecycle strategy for Xtandi® + Talzenna® in mCRPC. Before that, he was President of Pfizer Canada where he was accountable for the company’s operations within the country, including sales, marketing, access and government relations. He was also VP of a US commercial business unit which had tremendous growth under his leadership. Prior to working at Pfizer, Cole held management positions at both Hospira, Inc., a global pharmaceutical and medical device company, in global pharmaceuticals, global marketing and commercial development. He holds an MBA from the University of Chicago Booth School of Business, a Master of Science degree in Microbiology from Iowa State University, and a Bachelor’s Degree in Biology from St. Olaf College. In his spare time, Cole enjoys swimming, hiking and skiing.